The ARK Genomic Revolution ETF is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and U.S. exchange traded foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Funds investment theme of the genomics revolution.
* Volume delayed 20 minutes
Orders Accepted: Total Volume:
|Top of Book||Last 10 Trades|
About ARK Investment Management LLC
Founded in 2014, ARK Investment Management LLC is a New York based asset manager offering global thematic strategies that capitalize on the investment opportunities created by disruptive innovation. ARK believes that innovation is key to the long-term growth of company earnings, revenues and profits. By identifying and investing in public companies that are the leaders, enablers, and beneficiaries of disruptive innovation, ARK's strategies aim to deliver superior long-term capital appreciation and outperformance with low correlation to traditional investment strategies. With the launch of The 30 Printing ETF (PRNT), ARK's ETF division now manages five equity ETFs, with focuses on Genomics Revolution, Industrial Innovation, Next Generation Internet, and Disruptive Innovation (ARKG, ARKO, ARKW, ARKK). Catherine D. Wood founded ARK with over 35 years of experience in thematic investing, including her previous 12 years as the CIO of Global Thematic Strategies for AllianceBernstein managing over $5 billion.